Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in a rat model, 14,15-EET may alleviate central poststroke pain by enhancing thalamic inhibition through neurosteroid signaling, potentially outperforming gabapentin in early-stage treatment.

This abstract mentions that while synthetic drugs like minoxidil and finasteride for androgenic alopecia have side effects, the characteristics of popular natural alternatives, such as soybean, remain largely unreported, despite consumer preference for these products.

This study found that Avicennia marina extract and its active compound avicequinone C inhibit enzymes and receptors related to androgenic alopecia, potentially supporting hair growth in cultured dermal papilla cells.

This study found that spironolactone 100 mg daily did not demonstrate objective benefits in managing idiopathic hirsutism, as it increased hair shaft diameter without reducing serum androgen levels.

This review discusses spironolactone as an effective and potentially safer treatment for androgenic alopecia, particularly when used with minoxidil, but calls for more high-quality clinical trials.

This study found that the combination of spironolactone and finasteride significantly improved hirsutism scores more than spironolactone alone in women, with similar side-effect profiles between treatments.

This study found that astilbin downregulates effector CD4+ T cell activities through the CYP1B1/ROS/PPARγ pathway, suggesting its potential use in treating inflammation.

In this study, a combination of spironolactone and finasteride was found to significantly improve hirsutism scores without increasing side effects compared to spironolactone alone.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This study found that combining minoxidil and spironolactone was more effective for hair density and severity of hair loss in women with androgenic alopecia compared to minoxidil and finasteride, with no serious adverse effects reported.

This research on dermal papilla cells found that Sparasis crispa increased mRNA expression related to hair production and may help in hair generation cycles, but its impact on male hair loss treatment remains uncertain.

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.

This study found that Avicennia marina extract significantly inhibited 5α-reductase type 1 activity in human hair dermal papilla cells, suggesting its potential use for treating androgenic alopecia.

This research review found that spironolactone can significantly improve acne severity more effectively than a placebo, with 73.3% of patients reporting satisfaction despite a 26.7% rate of adverse events among the 1,548 participants studied.

This review discusses the pharmacological properties of progestins used in contraception and hormone replacement therapy, focusing on drospirenone's unique effects, but reports no new experimental findings.

This study found that spironolactone reduced testosterone production and urinary 17-ketosteroid excretion, leading to a decrease in hair growth rate and a change in hair texture in women.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

Both treatment combinations improved hair growth similarly and were safe.

This study found that the combination of finasteride and black soybean extract showed synergistic protective effects against DHT-induced damage in hair follicle cells, suggesting potential benefits for treating androgenetic alopecia.

This paper discusses spironolactone as a potential off-label treatment for female pattern hair loss, noting its ability to halt hair loss progression and induce partial regrowth in a significant number of women but reports no new clinical results.

This study concluded that S. hexaphylla extract may improve androgenetic alopecia by reducing 5α-reductase and androgen receptor levels, inhibiting apoptosis, and promoting keratinocyte proliferation in experimental models.

This study found that spironolactone at doses of 75 or 100 mg per day did not improve hair density after six months in women with female pattern hair loss, suggesting that higher doses may be necessary.

This study found that a proniosomal gel formulation of finasteride increased anagen hair count in male volunteers with androgenic alopecia by 42.85% compared to the control group.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This study found that phyto-vesicles of ß-sitosterol showed better absorption and improved activity for treating androgenetic alopecia in rats compared to the compound and its complex.

This study found that administering dutasteride did not change spermatogenesis or oxidative stress levels in rat testes, though further research is needed to confirm these findings.

In this study, spironolactone was reported to stabilize or improve female pattern hair loss in 74.3% of treated women, especially those with signs of hyperandrogenism.